A Novel Endogenous Amine, 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline(1BnTIQ) in Parkinsonian CSF, and Its Toxicological Effect

  • Y. Tasaki
  • Y. Kotake
  • Y. Makino
  • S. Ohta
  • M. Hirobe
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)


Recently there have been many reports in which 1,2,3,4-tetrahydroisoquinoline (TIQ) derivatives may be related to the onset of Parkinson’s disease.1–12 In these reports, we have already confirmed that TIQ and 1-methyl-TIQ (1MeTIQ) were detected in the brains of mice, rats, and humans; and the 1MeTIQ content in the parkinsonian brain was decreased in comparison with that in a normal subject’s brain, though the TIQ content was not changed in between both brains.1,2,8,13 In addition, pretreatment with 1MeTIQ perfectly prevented mice treated with TIQ or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) from bradykinesia, one of the characteristic symptoms in Parkinson’s disease. The slight difference in the structure between 1MeTIQ and TIQ, which is whether it has a methyl group at one position or not, induces a reverse effect (Figure 1).


Tyrosine Hydroxylase Mouse Brain Toxicological Effect Pole Test Chronic Ethanol Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. Kohno, S. Ohta, M. Hirobe, Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline as novel endogenous amines in rat brain, Biochem. Biophys. Res. Commun. 140: 448 (1986).PubMedCrossRefGoogle Scholar
  2. 2.
    S. Ohta, M. Kohno, Y. Makino, O. Tachikawa, and M. Hirobe, Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain, Biomed. Res. 8: 453 (1987).Google Scholar
  3. 3.
    T. Nagatsu, and Y. Hirata, Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4phenylpyridinium ion (MPP’) and the structurally related compounds in vitro and in vivo, Eur. Neurol. 26 (suppl. 1): 11 (1987).PubMedCrossRefGoogle Scholar
  4. 4.
    T. Niwa, N. Takeda, N. Kaneda, Y. Hashizume, and T. Nagatsu, Presence of tetrahydroisoquinoline in parkinsonian and normal human brains, Biochem. Biophys. Res. Commun. 144: 1084 (1987).PubMedCrossRefGoogle Scholar
  5. 5.
    K. Suzuki, Y. Mizuno, and M. Yoshida, Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline, Neurosci. Lett. 86: 105 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    T. Nagatsu, and M. Yoshida, An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions, Neurosci. Lett. 87: 178 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    G. Maret, B Testa, P Jenner, N. E. Tayar, and P-A Carrupt, Drug Metab. Rev. 22: 291 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    Y. Tasaki, Y. Makino, S. Ohta, and M. Hirobe, Methyl-1,2,3,4-tetrahydroioquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities,. 1. Neurochem. 57: 1940 (1991)CrossRefGoogle Scholar
  9. 9.
    S. Ohta, Y. Tasaki, Y. Makino, O. Tachikawa, and M. Hirobe, Importance of 1-methyltetrahydroisoquinoline(1MeTIQ) in Parkinson’s disease, in: “Basic, clinical and therapeutic aspects of Alzheimer’s and Parkinson’s disease, T. Nagatsu et al., ed., Plenum Press, New York, Vol. 1, (1990).Google Scholar
  10. 10.
    Y. Makino, Y. Tasaki, M. Kashiwasake, O. Tachikawa, and M. Hirobe, Formation of a novel and neurotoxic tetrahydroisoquinoline derivative, 1,3-dimethyltetrahydroisoquinoline (1,3DiMeTIQ), A condensation product of amphetamine in vivo, in: “Basic, clinical and therapeutic aspects of Alzheimer’s and Parkinson’s disease”, T. Nagatsu et al., ed., Plenum Press, New York, Vol. 1“, (1990).Google Scholar
  11. 11.
    M. Sandler, S. B. Carter, K. R. Hunter, and G. M. Stern, Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man, Nature 241: 439 (1973).PubMedCrossRefGoogle Scholar
  12. 12.
    Y, Makino, S. Ohta, Y. Tasaki, O. Tachikawa, and M. Kashiwasake, A novel and neurotoxic tetrahydroisoquinoline derivative in vivo: formation of 1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline, a condensation product of amphetamines, in brains of rats under chronic ethanol treatment, J. Neurochem. 55:963 (1990).CrossRefGoogle Scholar
  13. 13.
    Y. Makin, Y. Tasaki, S. Ohta, and M. Hirobe, Confirmation of the enantiomers of 1-methyl-1,2,3,4tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization, Biomed. Environ. Mass. Spectrom. 19: 415 (1990).CrossRefGoogle Scholar
  14. 14.
    K. Suzuki, Y. Mizuno, and M. Yoshida, Inhibition of mitochondrial respiration by 1,2,3,4tetrahydroisoquinoline-like endogenous alkaloids in mouse brain, Neurochem. Res. 15: 705 (1990).PubMedCrossRefGoogle Scholar
  15. 15.
    N. M. Gray, B. K. Cheng, S. J. Mick, C. M. Lair, and P. C. Contreras, Phencyclidine-like effects of tetrahydroisoquinolines and related compounds, J. Med. Chem. 32: 1242 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    H. Kawa, F. Yamaguchi, and N. Ishikawa, Optically active perfluoro-2-propoxypropionic acid: a new chiral reagent for“ F NMR study, J. Fluor. Chem. 20: 475 (1982).CrossRefGoogle Scholar
  17. 17.
    N. Ogawa, Y. Hirose, S. Ohara, T. Ono, and Y. Watanabe, A simple quantitative bradykinesia test in MPTP-treated mice, Res. Commun. Chem. Pathol. Pharmacol. 50: 435 (1985).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Y. Tasaki
    • 1
  • Y. Kotake
    • 1
  • Y. Makino
    • 1
  • S. Ohta
    • 2
  • M. Hirobe
    • 1
  1. 1.Faculty of Pharmaceutical SciencesUniversity of TokyoBunkyo-ku, Tokyo 113Japan
  2. 2.Faculty of MedicineUniversity of TokyoBunkyo-ku, Tokyo 113Japan

Personalised recommendations